{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang J"],"funding":["Guangdong Basic and Applied Basic Science Foundation","National Natural Science Foundation of China","Swedish Research Council supported by grants from the Swedish Research Council","European Union's Horizon Europe Research and Innovation Programme","National Key Research and Development Program of China","Shenzhen Bay Laboratory","Chongqing Science and Technology Bureau and the Health Commission","Swedish State Support for Clinical Research"],"pagination":["e70038"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11953589"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(3)"],"pubmed_abstract":["Introduction
This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD).Methods
The diagnostic performance of the Lumipulse G plasma p-tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort (n = 391) and a community cohort (n = 121).Results
Plasma p-tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p-tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p-tau217, Aβ42/Aβ40, p-tau181, and p-tau181/Aβ42 in both c"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts."],"pmcid":["PMC11953589"],"funding_grant_id":["2022-01018","ALFGBG-71320","81930028","S241101004-1","2023YFC3605400","2019-02397","82171197","2023-00356","2023B1515020113","82422027","101053962","2024GGXM003","S241101004‐1","92249305"],"pubmed_authors":["Bourgeat P","Lai YJ","Guo T","Zhang L","Zetterberg H","Wang J","Dore V","Sun P","Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN)","Bu XL","Chen Y","Liu YH","Li A","Chen X","Tang Y","Fripp J","Xiao ZS","Chen Q","Masters CL","Wang YJ","Huang S","Wang QH","He Z","Yu JT","Cai Y","Lan G","Zeng F"],"additional_accession":[]},"is_claimable":false,"name":"Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.","description":"Introduction
This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD).Methods
The diagnostic performance of the Lumipulse G plasma p-tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort (n = 391) and a community cohort (n = 121).Results
Plasma p-tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p-tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p-tau217, Aβ42/Aβ40, p-tau181, and p-tau181/Aβ42 in both c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-07-11T03:04:11.38Z","creation":"2025-07-11T03:04:11.38Z"},"accession":"S-EPMC11953589","cross_references":{"pubmed":["40156286"],"doi":["10.1002/alz.70038"]}}